Baird Reiterates an 'Outperform' on AMAG Pharmaceuticals (AMAG); Three Key Reasons to Remain Positive Including Takeout

Baird reiterates an 'Outperform' on AMAG Pharmaceuticals (NASDAQ: AMAG) price target of $21.00.

Analyst, Christopher Raymond, said, "Remain AMAG buyers following an in-line Q411 report, but lower-than-modeled FY12 guidance. With an EV/Sales ratio of <2.0, a key near-term data event (Phase III broad IDA trial this week), and a continued possibility for take-out, we continue to like this name despite tepid near-term growth in the base business. Continue to think this stock can work into the low $20s."

For an analyst ratings summary and ratings history on AMAG Pharmaceuticals click here. For more ratings news on AMAG Pharmaceuticals click here.

Shares of AMAG Pharmaceuticals closed at $16.09 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• UBS Reiterates Buy Rating on HF Sinclair (DINO)
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)